Log in

Start Your Membership Now

Member Engagement Models Reshaping The Economics Of SMI Service Delivery is starting in
About
Contact

Become A Member
Log in

Markets
Services
Customers

Market Intel Homepage

Search Library

Publications
Markets
Topics
Executive Institutes
Professional Development Programs
The OPEN MINDS Leadership & Management Certificate The OPEN MINDS CFO Consortium
Tools
Assessments
View By Topic View By Partner

Health Plan Trends

Population Health

The OPEN MINDS CFO Consortium

The OPEN MINDS Leadership & Management Certificate

Alera Health

ContinuumCloud

Otsuka

View By Topic View By Partner

Acute Care

AI In Process/Workflow Improvement

Clinically Integrated Systems Of Care

Employee Recruitment & Retention

Innovations in Autism & Behavioral Healthcare

Metrics-Based Mgmt//Data-Driven Decision Making

Quality Of Care

Transforming Data To Action

Workforce Optimization

AI/Advanced Technologies To Improve Outcomes

Automation Of Services/Processes

Concurrent Documentation

Hybrid/Virtual Care

Long-Term Services & Supports

Operational Excellence

Technology Strategy

Trauma Informed Approaches

AI in Analytics

CCBHCs

Crisis Management & Technology

Innovation

Medication-Assisted Treatment

Performance Management

Transformational Leadership For Non-Profits

Whole Person Care

ContinuumCloud

Netsmart

Cantata Health Solutions

Eleos

Grafton Integrated Health Network

Insperity

NextGen Healthcare

ServiceWorks

Vivant Behavioral Healthcare

Core Solutions

5e Analytics

Carelon

Five Points Technology Group

Hartman Executive Advisors

Juno Health

Radicle Health

Streamline Healthcare Solutions

Qualifacts

Altruix

CCNY

Genoa Healthcare

iCareManager

Mend

Relias

The BI Collaborative

Market Intelligence Resource | January 6, 2020

Warning Letter: RichSource Stem Cells, Inc.

On November 20, 2019, the U.S. Food and Drug Administration sent a warning letter to RichSource Stem Cells, Inc. The warning letter outlines a review conducted by the Office of Compliance and Biologics Quality in the Center for Biologics Evaluation and Research, noting that RICHGEN appears to be a human cell, tissue, or cellular or tissue-based product currently not meeting the criteria outlined in 21 CFR 1271.15 . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: